Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Protein Discovered that Amplifies Cell Death

By Drug Discovery Trends Editor | January 15, 2009

Scientists at Albert Einstein College of Medicine of Yeshiva University have identified a small intracellular protein that helps cells commit suicide. The finding could lead to drugs for combating cancer and other diseases characterized by overproduction of cells. The research was led by the late Dennis Shields, Ph.D., a professor in Einstein’s Department of Developmental and Molecular Biology for 30 years, who died unexpectedly in December.

In response to stress or as a natural part of aging, many cells undergo programmed suicide, also known as apoptosis. Cancer cells often become immortal and dangerous by developing the ability to suppress apoptosis.

A decade ago apoptosis was thought to be directed solely by the nucleus and mitochondria of cells. Dr. Shields’ laboratory showed that a cellular organelle known as the Golgi apparatus also plays a role in apoptosis.

The Golgi package proteins and other substances made by cells and direct them to their destination within the cell. A protein called p115 is vital for maintaining the structure of the Golgi. In earlier research, Dr. Shields’ group demonstrated that the Golgi’s p115 protein splits into two pieces early in apoptosis and that the smaller of these protein fragments — 205 amino acids in length — helps to maintain the cell-suicide process.

In the present study, the Einstein researchers identified the smallest region of this p115 protein fragment that is required for apoptosis: a peptide of just 26 amino acids in length that exerts its apoptotic action by traveling to the nucleus.

Release Date: January 14, 2009
Source: Albert Einstein College of Medicine


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50